Image

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class (Antidepressants, Hormone Therapy, Anticonvulsant, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) - Industry Trends and Forecast to 2029.

Vasomotor Menopausal Symptoms (VMS) Treatment Market

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Analysis and Insights

Up to 75% of females in the United States witness hot flashes around menopause, according to the North American Menopause Society. Vasomotor symptoms (VMS), including night sweats and hot flashes, are witnessed in as many as 68.5% of women as a result of menopause. The median duration of these symptoms is 4 years, although approximately 10% of women continue to experience VMS as many as 12 years.

  • Vasomotor symptoms (VMS) have a significant impact on women's quality of life and overall physical health. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market was valued at USD 15.73 billion in 2021 and is expected to reach USD 24.51 billion by 2029, registering a CAGR of 5.70% during the forecast period of 2022-2029.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics

Drivers

  • Surge in Menopause Population

The increase in the number of menopausal women demanding treatment for hot flashes and vaginal dryness across the globe is one of the major factors driving the growth of the vasomotor menopausal symptoms (VMS) treatment market.

  • Increase In Mergers and Acquisitions

The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options are resulting in the expansion of the market.

  • Sedentary Life Style

The rise in the adoption of a sedentary lifestyle and lack of physical activity among the population causing increased cases of these symptoms accelerate the vasomotor menopausal symptoms (VMS) treatment market growth.

  • Financial support to the researchers for developing novel intervention

Various public and private organizations are increasing their investments in developing novel interventions and treatments that further influence the market.

Additionally, surge in healthcare expenditure, increase in demand for effective therapies, and development in technology positively affect the vasomotor menopausal symptoms (VMS) treatment market growth.

Opportunities

Furthermore, development of novel treatment extends profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, a rise in awareness about menopause symptoms will escalate the growth of the growth of the vasomotor menopausal symptoms (VMS) treatment market.

Restraints/Challenges Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

On the other hand, adverse effects associated with drugs and stringent regulatory policies are are expected to obstruct the market growth. The generic competitions of drugs are projected to challenge the vasomotor menopausal symptoms (VMS) treatment market growth in the forecast period of 2022-2029.

This vasomotor menopausal symptoms (VMS) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on vasomotor menopausal symptoms (VMS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Menopause generally begins between 45 and 58 years in the U.S. The average age for menopause is 52 years, where an individual enters menopause 12 months after their last period. Hot flashes and other symptoms can start during perimenopause, or they may begin after a person’s periods end.

The vasomotor menopausal symptoms (VMS) treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Vasomotor Menopausal Symptoms (VMS) Treatment Market

The COVID-19 negatively impacted the vasomotor menopausal symptoms (VMS) treatment market. The pandemic outbreak caused disruption in the supply chains of the drugs that lead to supply gaps for countries dependent on trade affairs for drugs. However, the post-second wave of supply chain disruptions and logistics are being eased.

https://www.marketresearchfuture.com/reports/vasomotor-symptoms-market-9810

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

The myeloid leukemia treatment market is segmented on the basis of drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Antidepressants
  • Hormone Therapy
  • Anticonvulsant
  • Others

Based on drug class, the global vasomotor menopausal symptoms (VMS) treatment market is segmented into antidepressants, hormone therapy, anticonvulsant and others.

Route of Administration

  • Oral
  • Parenteral
  • Others

Route of administration segment of global vasomotor menopausal symptoms (VMS) treatment market is segmented into oral, parenteral and others.

End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

On the basis of end-users, the global vasomotor menopausal symptoms (VMS) treatment market is segmented into hospitals, homecare, specialty clinics and others.

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

On the basis of distribution channel, the global vasomotor menopausal symptoms (VMS) treatment market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.

Pipeline Analysis

The purpose of hormone therapy is balancing hormone levels in the body, and can help relieve hot flashes and other symptoms. The hormonal therapy include the use of estrogen, progesterone, and combination. Zhejiang Huahai Pharmaceutical Co., Ltd, and Teva Pharmaceutical Industries Ltd, among others are some of the manufacturers involved with the development of menopausal symptoms.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional Analysis/Insights

The vasomotor menopausal symptoms (VMS) treatment market is analysed and market size insights and trends are provided by country, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the vasomotor menopausal symptoms (VMS) treatment market due to the presence of wee-developed healthcare infrastructure and high consumer awareness within the region.

Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the rise in target population in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Vasomotor Menopausal Symptoms (VMS) Treatment Market Share Analysis

The vasomotor menopausal symptoms (VMS) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to vasomotor menopausal symptoms (VMS) treatment market.

Some of the major players operating in the vasomotor menopausal symptoms (VMS) treatment market are Zhejiang Huahai Pharmaceutical Co., Ltd, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Alembic Pharmaceuticals Limited, Zydus Cadila, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Allergan, Sun Pharmaceutical Industries Ltd, Apotex Inc, Aurobindo Pharma, Endo Pharmaceuticals plc, Lupin, Novartis AG, and WOCKHARDT among others.

Customization Available : Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Research Methodology : Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-vasomotor-menopausal-symptoms-vms-treatment-market


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Vasomotor Menopausal Symptoms (VMS) Treatment Market will be projected to grow at a CAGR of 5.70% during the forecast by 2029.
The Vasomotor Menopausal Symptoms (VMS) Treatment Market will be projected at USD 24.51 billion during the forecast by 2029.
The major players operating in the Vasomotor Menopausal Symptoms (VMS) Treatment Market are Zhejiang Huahai Pharmaceutical Co., Ltd, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Alembic Pharmaceuticals Limited, Zydus Cadila, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Allergan, Sun Pharmaceutical Industries Ltd, Apotex Inc, Aurobindo Pharma, Endo Pharmaceuticals plc, Lupin, Novartis AG, and WOCKHARDT among others.
The significant factors flourishing the growth of the Vasomotor Menopausal Symptoms (VMS) Treatment Market are Surge in Menopause Population, Increase In Mergers and Acquisitions, and Financial support to the researchers for developing novel intervention.